Department of Cell Biology, School of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang, 212003, Jiangsu, China.
J Cancer Res Clin Oncol. 2021 Sep;147(9):2489-2505. doi: 10.1007/s00432-021-03701-8. Epub 2021 Jun 19.
Tumor recurrence after the clinical cure of tumor often results from the presence of an abnormal microenvironment, including an aberrant vasculature. The tumor microenvironment is rich in pro-angiogenic factors but lacks pro-maturation factors. Pro-angiogenic conditions in the tumor microenvironment, such as hypoxia, are double-edged swords, promoting both the repair of normal tissues and the development of an abnormal blood vessel network. The coexistence of perfusion and hypoxic zones and uneven blood vessel distribution in tumor tissues profoundly influence tumor deterioration, recurrence, and metastasis. Traditional anti-angiogenic therapies have shown limited efficacy, and promote drug resistance, and even metastasis. In contrast, vascular normalization therapy induces a more physiological-like state, leading to better outcomes and fewer side effects. Vascular normalization entails modifying the tumor vascular system to improve tumor oxygenation and substance transport, thereby contributing to improving the efficacy of radiotherapy, chemotherapy, and immunotherapy. This review mainly focuses on the process of tumor vascularization; potential therapeutic targets, including cells, metabolism, signaling pathways, and angiogenesis-related genes; and possible strategies to normalize blood vessels through regulating tumor vessel generation, the development of tumor vessels, and blood vessel fusion and pruning.
肿瘤临床治愈后复发通常是由于异常微环境的存在,包括异常的脉管系统。肿瘤微环境富含促血管生成因子,但缺乏促成熟因子。肿瘤微环境中的促血管生成条件(如缺氧)是一把双刃剑,既促进正常组织的修复,又促进异常血管网络的形成。肿瘤组织中灌注区和缺氧区的共存以及血管分布不均匀,极大地影响了肿瘤的恶化、复发和转移。传统的抗血管生成治疗效果有限,并促进了耐药性的产生,甚至导致转移。相比之下,血管正常化治疗诱导出更接近生理的状态,从而带来更好的疗效和更少的副作用。血管正常化涉及改变肿瘤血管系统,以改善肿瘤的氧合和物质转运,从而有助于提高放疗、化疗和免疫治疗的疗效。本综述主要聚焦于肿瘤血管生成的过程;潜在的治疗靶点,包括细胞、代谢、信号通路和血管生成相关基因;以及通过调节肿瘤血管生成、肿瘤血管发育和血管融合与修剪来实现血管正常化的可能策略。
J Cancer Res Clin Oncol. 2021-9
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2017-6-22
Semin Immunopathol. 2024-7-11
Cochrane Database Syst Rev. 2012-7-11
Biomed Pharmacother. 2017-11-6
Arch Ital Urol Androl. 2025-6-30
Biology (Basel). 2024-4-28
Sensors (Basel). 2020-8-12
Proc Natl Acad Sci U S A. 2020-2-3
Proc Natl Acad Sci U S A. 2019-12-30